AAPL   234.04 (-0.54%)
FB   188.03 (-0.46%)
MSFT   139.70 (-1.33%)
GOOGL   1,245.59 (+0.27%)
AMZN   1,775.35 (+0.45%)
CGC   19.31 (-3.93%)
MU   46.22 (-0.50%)
BABA   174.37 (-0.52%)
GE   8.98 (+1.01%)
TSLA   258.01 (+0.05%)
T   37.94 (+0.11%)
F   9.14 (+0.66%)
ACB   3.62 (-3.73%)
NFLX   284.06 (-0.07%)
BAC   30.27 (+1.82%)
GILD   65.46 (+0.25%)
DIS   129.82 (+0.05%)
AAPL   234.04 (-0.54%)
FB   188.03 (-0.46%)
MSFT   139.70 (-1.33%)
GOOGL   1,245.59 (+0.27%)
AMZN   1,775.35 (+0.45%)
CGC   19.31 (-3.93%)
MU   46.22 (-0.50%)
BABA   174.37 (-0.52%)
GE   8.98 (+1.01%)
TSLA   258.01 (+0.05%)
T   37.94 (+0.11%)
F   9.14 (+0.66%)
ACB   3.62 (-3.73%)
NFLX   284.06 (-0.07%)
BAC   30.27 (+1.82%)
GILD   65.46 (+0.25%)
DIS   129.82 (+0.05%)
Log in

ResMed Stock Price, News & Analysis (NYSE:RMD)

+0.09 (+0.07 %)
(As of 10/16/2019 10:13 AM ET)
Today's Range
Now: $130.54
50-Day Range
MA: $134.31
52-Week Range
Now: $130.54
Volume3,878 shs
Average Volume510,134 shs
Market Capitalization$18.77 billion
P/E Ratio35.83
Dividend Yield1.20%
ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications that diagnose, treat, and manage respiratory disorders comprising sleep disordered breathing, chronic obstructive pulmonary disease, neuromuscular disease, and other chronic diseases. It offers various products and solutions for a range of respiratory disorders, including technologies to be applied in medical and consumer products, ventilation devices, diagnostic products, mask systems for use in the hospital and home, headgear and other accessories, dental devices, portable oxygen concentrators, and cloud-based software informatics solutions to manage patient outcomes, as well as provides customer and business processes. Read More…

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment



Sales & Book Value

Annual Sales$2.61 billion
Cash Flow$4.75 per share
Book Value$14.42 per share


Net Income$404.59 million


Market Cap$18.77 billion
Next Earnings Date10/24/2019 (Confirmed)

Receive RMD News and Ratings via Email

Sign-up to receive the latest news and ratings for RMD and its competitors with MarketBeat's FREE daily newsletter.

ResMed (NYSE:RMD) Frequently Asked Questions

What is ResMed's stock symbol?

ResMed trades on the New York Stock Exchange (NYSE) under the ticker symbol "RMD."

How often does ResMed pay dividends? What is the dividend yield for ResMed?

ResMed declared a quarterly dividend on Thursday, July 25th. Shareholders of record on Thursday, August 15th will be given a dividend of $0.39 per share on Thursday, September 19th. This represents a $1.56 dividend on an annualized basis and a yield of 1.20%. The ex-dividend date of this dividend is Wednesday, August 14th. This is an increase from ResMed's previous quarterly dividend of $0.37. View ResMed's Dividend History.

How were ResMed's earnings last quarter?

ResMed Inc. (NYSE:RMD) posted its earnings results on Thursday, July, 25th. The medical equipment provider reported $0.95 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.92 by $0.03. The medical equipment provider earned $705 million during the quarter, compared to the consensus estimate of $701.56 million. ResMed had a return on equity of 26.49% and a net margin of 15.52%. The business's revenue for the quarter was up 13.1% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.95 earnings per share. View ResMed's Earnings History.

When is ResMed's next earnings date?

ResMed is scheduled to release their next quarterly earnings announcement on Thursday, October 24th 2019. View Earnings Estimates for ResMed.

How can I listen to ResMed's earnings call?

ResMed will be holding an earnings conference call on Thursday, October 24th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

What price target have analysts set for RMD?

6 equities research analysts have issued 12-month price objectives for ResMed's stock. Their forecasts range from $95.00 to $140.00. On average, they expect ResMed's stock price to reach $118.33 in the next year. This suggests that the stock has a possible downside of 9.4%. View Analyst Price Targets for ResMed.

What is the consensus analysts' recommendation for ResMed?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for ResMed in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for ResMed.

Has ResMed been receiving favorable news coverage?

Media coverage about RMD stock has trended very negative on Wednesday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. ResMed earned a coverage optimism score of -3.3 on InfoTrie's scale. They also assigned headlines about the medical equipment provider a news buzz of 8.0 out of 10, meaning that recent news coverage is very likely to have an impact on the company's share price in the near future. View News Stories for ResMed.

Are investors shorting ResMed?

ResMed saw a decline in short interest in September. As of September 30th, there was short interest totalling 1,910,000 shares, a decline of 18.0% from the August 30th total of 2,330,000 shares. Based on an average daily trading volume, of 513,800 shares, the days-to-cover ratio is presently 3.7 days. Approximately 1.3% of the company's shares are short sold. View ResMed's Current Options Chain.

Who are some of ResMed's key competitors?

What other stocks do shareholders of ResMed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ResMed investors own include Energy Transfer LP Unit (ET), Starbucks (SBUX), Netflix (NFLX), Walt Disney (DIS), Visa (V), Mastercard (MA), CBL & Associates Properties (CBL), AT&T (T), Intel (INTC) and Ford Motor (F).

Who are ResMed's key executives?

ResMed's management team includes the folowing people:
  • Mr. Michael J. Farrell BE, SM, MBA, CEO & Director (Age 47)
  • Mr. Robert A. Douglas, Pres & COO (Age 59)
  • Mr. Brett A. Sandercock, Chief Financial Officer (Age 52)
  • Mr. David B. Pendarvis, Chief Admin. Officer, Global Gen. Counsel & Sec. (Age 60)
  • Mr. James Hollingshead, Pres of Sleep Bus. (Age 56)

Who are ResMed's major shareholders?

ResMed's stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Welch & Forbes LLC (0.21%), Capital Investment Services of America Inc. (0.11%), Gateway Investment Advisers LLC (0.08%), Security National Bank (0.03%), State of Alaska Department of Revenue (0.03%) and Gulf International Bank UK Ltd (0.02%). Company insiders that own ResMed stock include Brett Sandercock, David Pendarvis, Gary W Pace, James Hollingshead, John P Wareham, Michael J Farrell, Peter C Farrell, Rajwant Sodhi, Richard Mchale, Richard Sulpizio, Robert Andrew Douglas and Ronald R Taylor. View Institutional Ownership Trends for ResMed.

Which major investors are selling ResMed stock?

RMD stock was sold by a variety of institutional investors in the last quarter, including Crossmark Global Holdings Inc., Gateway Investment Advisers LLC, Welch & Forbes LLC, Gulf International Bank UK Ltd, Rockland Trust Co., First Hawaiian Bank and Financial Gravity Wealth Inc.. Company insiders that have sold ResMed company stock in the last year include Brett Sandercock, David Pendarvis, James Hollingshead, John P Wareham, Michael J Farrell, Rajwant Sodhi, Richard Mchale, Robert Andrew Douglas and Ronald R Taylor. View Insider Buying and Selling for ResMed.

Which major investors are buying ResMed stock?

RMD stock was bought by a variety of institutional investors in the last quarter, including Landsberg Bennett & Dubbaneh LLC, State of Alaska Department of Revenue, Surevest Inc., Campbell Capital Management Inc., Patten & Patten Inc. TN, Park National Corp OH, Starfire Investment Advisers Inc. and Pacer Advisors Inc.. View Insider Buying and Selling for ResMed.

How do I buy shares of ResMed?

Shares of RMD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is ResMed's stock price today?

One share of RMD stock can currently be purchased for approximately $130.54.

How big of a company is ResMed?

ResMed has a market capitalization of $18.77 billion and generates $2.61 billion in revenue each year. The medical equipment provider earns $404.59 million in net income (profit) each year or $3.64 on an earnings per share basis. ResMed employs 7,240 workers across the globe.View Additional Information About ResMed.

What is ResMed's official website?

The official website for ResMed is http://www.resmed.com/.

How can I contact ResMed?

ResMed's mailing address is 9001 SPECTRUM CENTER BLVD., SAN DIEGO CA, 92123. The medical equipment provider can be reached via phone at 858-836-5000 or via email at [email protected]

MarketBeat Community Rating for ResMed (NYSE RMD)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  314 (Vote Outperform)
Underperform Votes:  582 (Vote Underperform)
Total Votes:  896
MarketBeat's community ratings are surveys of what our community members think about ResMed and other stocks. Vote "Outperform" if you believe RMD will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RMD will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel